ImmuDyne Announces Completion of Shapiro MD Formulation Work and Update on Launch

MT. KISCO, N.Y., March 23, 2017 -- ImmuDyne, Inc. (OTCQB:IMMD) (“ImmuDyne” or the “Company”), a leader in the development and marketing of OTC healthcare products, today announces that all formulation work has been completed on the Shapiro MD product line.  The first product run will occur within the next 2-3 weeks and we anticipate a national product launch no later than April 15, 2017.

In addition to the Shampoo and Conditioner, ImmuDyne also formulated a once-daily leave in foam product that the Company believes will be a strong addition to the product line.  Collectively, these products represent the most researched, all natural and patented hair loss product line on the market.

“ImmuDyne and our Puerto Rico based subsidiary have been receiving strong and almost daily interest from leading publishers around the country that want to be the first to offer this innovative product line,” stated Mark McLaughlin, Chief Executive Officer of ImmuDyne. “I believe this high level of interest from such respected parties speaks to the caliber of the science behind the Shapiro MD products and the huge market need for a differentiated product that works in the hair loss vertical.”

“We always knew that in the right hands, the Shapiro MD products would be very successful,” said Dr. Steven Shapiro.  "We’re very excited for the product launch and are very optimistic that the 10 years we invested in research and development to create Shapiro MD will benefit people around the world that want an all-natural solution for thicker and fuller hair.”

ImmuDyne will continue to keep shareholders and the public apprised of all important milestones related to the launch of Shapiro MD.

About lmmuDyne
lmmuDyne, Inc. (the "Company") is a health and wellness company which develops, manufactures, markets, and sells innovative lifestyle products. The Company's lead products contain its proprietary yeast beta glucans that have been shown through testing and analysis to support the immune system. The Company's products include once a day oral intake capsules as well as topical serums and creams for skin application. lmmuDyne also has developed a proprietary natural delivery technology for potential new market opportunities. All of lmmuDyne's intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com.

Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward­ looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release, including projections with respect to lmmuDyne's results of operations, may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans,"  "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

Contact:
ImmuDyne, Inc.
Mark McLaughlin: +1-914-714-8901